Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

160.61 +2.61 (+1.65%)

Delayed Quote Updated: 3:18 PM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Alnylam Shares Detailed Patisiran Data From Rare Disease Study ↗

September 08, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

September 08, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference

September 06, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Where Alnylam Pharmaceuticals Stands With Analysts ↗

August 04, 2022

Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:

Via Benzinga

Why Is Alnylam (ALNY) Stock Up 50% Today? ↗

August 03, 2022

ALNY stock is quickly moving higher as Wall Street weighs Alnylam's encouraging results for a hard-to-treat condition.

Via InvestorPlace

Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug ↗

August 29, 2022

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy

August 29, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know ↗

August 26, 2022

Moderna Inc (NASDAQ: MRNA) has

Via Benzinga

Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors

August 24, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis

August 18, 2022

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart? ↗

August 17, 2022

If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today ↗

August 12, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 9.06% on an annualized basis producing an average annual return of 16.5%. Currently, Alnylam...

Via Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review ↗

August 05, 2022

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

Via Investor's Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug ↗

August 05, 2022

The company will compete with Pfizer, which already has an approved drug.

Via Investor's Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned ↗

August 04, 2022

Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients.

Via Investor's Business Daily

Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

August 04, 2022

Alnylam Pharmaceuticals (NASDAQ:ALNY) brought in sales totaling $224.82 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 15.42%, resulting in a loss of $277.40...

Via Benzinga

Moderna, PayPal And Some Other Big Gainers From Wednesday ↗

August 04, 2022

U.S. stocks closed higher on Wednesday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 03, 2022

Via Benzinga

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 03, 2022

Via Benzinga

What Is Going on With Helius Medical (HSDT) Stock Today? ↗

August 03, 2022

Helius Medical (HSDT) stock is rocketing higher on Wednesday despite a lack of news from the medical device holding company.

Via InvestorPlace

Alnylam Shares Shoot Higher Following Positive Clinical Results From Late-Stage ATTR Amyloidosis Therapeutics ↗

August 03, 2022

Alnylam (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of Patisiran for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alnylam Pharmaceuticals Is On Track To Hit A Record High — Here's Why ↗

August 03, 2022

Alnylam stock is on track to open at a record high Wednesday after its cardiomyopathy drug met every goal in a final-phase study.

Via Investor's Business Daily

Why Alnylam Pharma Shares Are Trading Higher During Premarket Session ↗

August 03, 2022

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) shares are rallying after upbeat data from APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 03, 2022

Via Benzinga

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.